Compare MLYS & ETJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLYS | ETJ |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 543.8M |
| IPO Year | 2023 | 2007 |
| Metric | MLYS | ETJ |
|---|---|---|
| Price | $29.17 | $8.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $48.67 | N/A |
| AVG Volume (30 Days) | ★ 998.0K | 152.6K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.59 | $7.88 |
| 52 Week High | $47.65 | $9.12 |
| Indicator | MLYS | ETJ |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 56.25 |
| Support Level | $26.85 | $8.30 |
| Resistance Level | $31.19 | $9.04 |
| Average True Range (ATR) | 1.58 | 0.09 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 65.43 | 74.07 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.